Cargando…
Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation
PURPOSE: Myocardial infarction is a major cause of mortality and heart failure worldwide. One of the most effective methods of this injury is direct delivery of cardioprotective drugs to ischemia–reperfusion (IR) myocardium. The aim of the present study was to fabricate an adenosine (Ade) prodrug-ba...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001834/ https://www.ncbi.nlm.nih.gov/pubmed/29928113 http://dx.doi.org/10.2147/DDDT.S166749 |
_version_ | 1783332087058661376 |
---|---|
author | Yu, Jianjun Li, Wei Yu, Dongmei |
author_facet | Yu, Jianjun Li, Wei Yu, Dongmei |
author_sort | Yu, Jianjun |
collection | PubMed |
description | PURPOSE: Myocardial infarction is a major cause of mortality and heart failure worldwide. One of the most effective methods of this injury is direct delivery of cardioprotective drugs to ischemia–reperfusion (IR) myocardium. The aim of the present study was to fabricate an adenosine (Ade) prodrug-based, atrial natriuretic peptide (ANP)-modified nanosystem for the treatment of myocardial infarction. MATERIALS AND METHODS: Oleate adenosine prodrug (Ade-OA) and ANP-distearoylphosphatidylethanolamine-polyethylene glycol were synthesized. ANP-modified Ade-loaded lipid nanocarriers (ANP Ade/LNCs) were then self-assembled by using solvent evaporation method. In vitro drug release in the presence of plasma was evaluated. In vivo inhibition effect on infarct size, tissue distribution, and pharmacokinetics were investigated in rats with ischemic myocardium after intravenous injection. RESULTS: In vivo inhibition effect on infarct size, tissue distribution, and pharmacokinetics studies in acute myocardial infarction (AMI) rats showed that ANP Ade/LNCs exhibited better efficiency than non-modified Ade/LNCs and free Ade in all respects. CONCLUSION: These results indicated that the ANP Ade/LNCs can be used as a promising system for the treatment of cardiovascular diseases. |
format | Online Article Text |
id | pubmed-6001834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60018342018-06-20 Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation Yu, Jianjun Li, Wei Yu, Dongmei Drug Des Devel Ther Original Research PURPOSE: Myocardial infarction is a major cause of mortality and heart failure worldwide. One of the most effective methods of this injury is direct delivery of cardioprotective drugs to ischemia–reperfusion (IR) myocardium. The aim of the present study was to fabricate an adenosine (Ade) prodrug-based, atrial natriuretic peptide (ANP)-modified nanosystem for the treatment of myocardial infarction. MATERIALS AND METHODS: Oleate adenosine prodrug (Ade-OA) and ANP-distearoylphosphatidylethanolamine-polyethylene glycol were synthesized. ANP-modified Ade-loaded lipid nanocarriers (ANP Ade/LNCs) were then self-assembled by using solvent evaporation method. In vitro drug release in the presence of plasma was evaluated. In vivo inhibition effect on infarct size, tissue distribution, and pharmacokinetics were investigated in rats with ischemic myocardium after intravenous injection. RESULTS: In vivo inhibition effect on infarct size, tissue distribution, and pharmacokinetics studies in acute myocardial infarction (AMI) rats showed that ANP Ade/LNCs exhibited better efficiency than non-modified Ade/LNCs and free Ade in all respects. CONCLUSION: These results indicated that the ANP Ade/LNCs can be used as a promising system for the treatment of cardiovascular diseases. Dove Medical Press 2018-06-11 /pmc/articles/PMC6001834/ /pubmed/29928113 http://dx.doi.org/10.2147/DDDT.S166749 Text en © 2018 Yu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Yu, Jianjun Li, Wei Yu, Dongmei Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation |
title | Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation |
title_full | Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation |
title_fullStr | Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation |
title_full_unstemmed | Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation |
title_short | Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation |
title_sort | atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001834/ https://www.ncbi.nlm.nih.gov/pubmed/29928113 http://dx.doi.org/10.2147/DDDT.S166749 |
work_keys_str_mv | AT yujianjun atrialnatriureticpeptidemodifiedoleateadenosineprodruglipidnanocarriersforthetreatmentofmyocardialinfarctioninvitroandinvivoevaluation AT liwei atrialnatriureticpeptidemodifiedoleateadenosineprodruglipidnanocarriersforthetreatmentofmyocardialinfarctioninvitroandinvivoevaluation AT yudongmei atrialnatriureticpeptidemodifiedoleateadenosineprodruglipidnanocarriersforthetreatmentofmyocardialinfarctioninvitroandinvivoevaluation |